Aradigm Health’s CEO discusses how payers and other entities in the healthcare ecosystem are developing strategies to ensure cell & gene therapy costs don’t prevent patients from accessing them.
Will Shrank
Advertisement
Will Shrank is CEO of Aradigm Health.
Articles by Will Shrank
Aradigm Health CEO Will Shrank discusses the shift in value-based care models for cell and gene therapies.
Will Shrank, Aradigm Health’s CEO, discusses the importance of transparency in healthcare payments to build trust and reduce waste.
Aradigm CEO Will Shrank discusses the significant challenge payers face in predicting and managing the costs of cell and gene therapies due to their volatility and unpredictability.
Will Shrank, CEO of Aradigm Health, discusses the fragmented payment and delivery system and its impact on cell & gene therapies.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
The Evolving Relationship Between FDA and Biotech
2
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
3
The Implications of GLP-1s Replacing Oncology as the Key Value Driver
4
Pharma M&A Roundup: Gilead Sciences Expands Collaboration with World Health Organization, Johnson & Johnson Enters Collaboration with Department of Health - Abu Dhabi
5